Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1452910 | 0.74 | IDO1 (0.48) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL852178 | 0.74 | IDO1 (0.48) | IDO1LMNATAAR1AGXTMAOB | |
| SCHEMBL1444597 | 0.74 | IDO1 (0.48) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL2821261 | 0.74 | CYP2A6 (0.44) | IDO1CYP2A6TAAR1HTR2AMAOB | |
| SCHEMBL29892302 | 0.73 | — | — | |
| SCHEMBL1106684 | 0.71 | IDO1 (0.58) | IDO1LMNACYP2A6TAAR1AGXT | |
| SCHEMBL2135113 | 0.71 | TAAR1 (0.68) | IDO1LMNACYP2A6TAAR1AGXT | |
| Hydrochloric Acid SCHEMBL2271064 | 0.71 | CALM1 (0.45) | IDO1CYP2A6TAAR1AGXTHTR2A | |
| Bromide SCHEMBL1444600 | 0.71 | CALM1 (0.45) | IDO1CYP2A6TAAR1HTR2AMAOB | |
| SCHEMBL622228 | 0.70 | IDO1 (0.56) | IDO1TAAR1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2021-01-07 | — | — | US | disclosed |
| EP-2699562-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | PFIZER INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | PFIZER INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10144742-B2 | Quinoxaline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005105777-A1 | SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE | 2004-12-30 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003031458-A1 | METHODS FOR SYNTHESIS OF DIARYLMETHANES | DANA-FARBER CANCER INSTITUTE (US) | 2003-04-17 | — | — | WO | disclosed |
| US-5498750-A | Process for the preparation of 1-fluoro-cyclopropane-1-carboxylic acid | BAYER AKTIENGESELLSCHAFT (DE) | 1996-03-12 | — | — | US | disclosed |
| US-5434303-A | Process for the preparation of 1-fluoro-cyclopropane-1-carboxylic acid | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266513-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | IDO1 595/4885LMNA 4038/4885CYP2A6 2845/4885 |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | IDO1 286/4885LMNA 3346/4885CYP2A6 175/4885 |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DHFR, DPYD, DHODH | IDO1 277/4885LMNA 3339/4885CYP2A6 103/4885 |
| US-10144742-B2 | Quinoxaline compounds and uses thereof | NAMPT, NQO2, NNMT | IDO1 55/4885LMNA 3814/4885CYP2A6 2902/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | IDO1 2313/4885LMNA 646/4885CYP2A6 684/4885 |
| US-10815213-B2 | Bruton's tyrosine kinase inhibitors | BTK, LCK, LYN | IDO1 697/4885LMNA 4047/4885CYP2A6 2248/4885 |
| US-20210002251-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, LYN | IDO1 697/4885LMNA 4047/4885CYP2A6 2248/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | IDO1 2313/4885LMNA 646/4885CYP2A6 684/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | IDO1 2313/4885LMNA 646/4885CYP2A6 684/4885 |
| US-20190202798-A1 | Bruton's Tyrosine Kinase Inhibitors | BTK, LCK, SYK | IDO1 694/4885LMNA 4037/4885CYP2A6 2102/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | IDO1 329/4885LMNA 2102/4885CYP2A6 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.